What is the evidence supporting the use of rituximab in crescentic IgA nephropathy?
Year: 2026
Type: article
Abstract: Evidence for rituximab in crescentic IgA nephropathy is limited but includes observations of proteinuria reduction and potential relapse risk reduction when combined with corticosteroids compared to steroid monotherapy.
Author: Tripdatabase
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7235268193
